One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
History of Medicine: HIPAA at 25 — A Work in Progress
Anita L. Allen, J.D., Ph.D.
doi : 10.1056/NEJMp2100900
N Engl J Med 2021; 384:2169-2171
HIPAA and the Leak of “Deidentified” EHR Data
Kenneth D. Mandl, M.D., M.P.H., and Eric D. Perakslis, Ph.D.
doi : 10.1056/NEJMp2102616
N Engl J Med 2021; 384:2171-2173
What Did I Sign Up For?
Jaclyn Heilman, M.D.
doi : 10.1056/NEJMp2103371
N Engl J Med 2021; 384:2173-2175
Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue
Adi Utarini, M.D., Ph.D., Citra Indriani, M.D., M.P.H., Riris A. Ahmad, M.D., Ph.D., Warsito Tantowijoyo, Ph.D., et al., for the AWED Study Group*
doi : 10.1056/NEJMoa2030243
N Engl J Med 2021; 384:2177-2186
Aedes aegypti mosquitoes infected with the wMel strain of Wolbachia pipientis are less susceptible than wild-type A. aegypti to dengue virus infection.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Jerald Sadoff, M.D., Glenda Gray, M.B., B.Ch., An Vandebosch, Ph.D., Vicky C?rdenas, Ph.D., et al., for the ENSEMBLE Study Group*
doi : 10.1056/NEJMoa2101544
N Engl J Med 2021; 384:2187-2201
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation.
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Marie Scully, M.D., Deepak Singh, B.Sc., Robert Lown, M.D., Anthony Poles, M.D., et al.
doi : 10.1056/NEJMoa2105385
N Engl J Med 2021; 384:2202-2211
The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity.
Brief Report: Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Ezgi Hacisuleyman, Ph.D., Caryn Hale, Ph.D., Yuhki Saito, Ph.D., Nathalie E. Blachere, Ph.D., et al.
doi : 10.1056/NEJMoa2105000
N Engl J Med 2021; 384:2212-2218
Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018
Michael Fang, Ph.D., Dan Wang, M.S., Josef Coresh, M.D., Ph.D., and Elizabeth Selvin, Ph.D., M.P.H.
doi : 10.1056/NEJMsa2032271
N Engl J Med 2021; 384:2219-2228
Recent Advances in the Treatment of Melanoma
Brendan D. Curti, M.D., and Mark B. Faries, M.D.
doi : 10.1056/NEJMra2034861
N Engl J Med 2021; 384:2229-2240
Orbital Cowpox
Miles Kiernan, F.R.C.Ophth., and Nikolaos Koutroumanos, F.R.C.Ophth.
doi : 10.1056/NEJMicm2033620
N Engl J Med 2021; 384:2241
Porphyria Cutanea Tarda Associated with Hepatitis C
Tejesh S. Patel, M.D., and Evgeniya Teterina Mohammed, M.D.
doi : 10.1056/NEJMicm2035140
N Engl J Med 2021; 384:e86
Case 17-2021: An 82-Year-Old Woman with Pain, Swelling, and Ecchymosis of the Left Arm
Kathleen M. Finn, M.D., M.Phil., Patrick D. Sutphin, M.D., Jonathan C.T. Carlson, M.D., Ph.D., Kevin A. Raskin, M.D., et al.
doi : 10.1056/NEJMcpc2100281
N Engl J Med 2021; 384:2242-2250
Dengue — Perils and Prevention
Davidson H. Hamer, M.D.
doi : 10.1056/NEJMe2107325
N Engl J Med 2021; 384:2252-2253
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Douglas B. Cines, M.D., and James B. Bussel, M.D.
doi : 10.1056/NEJMe2106315
N Engl J Med 2021; 384:2254-2256
Audio Interview: Treating Complications of Covid Vaccination
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Dan L. Longo, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2109757
N Engl J Med 2021; 384:e107
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
doi : 10.1056/NEJMc2103916
N Engl J Med 2021; 384:2259-2261
Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis
doi : 10.1056/NEJMc2105498
N Engl J Med 2021; 384:e90
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and ?-Thalassemia
doi : 10.1056/NEJMc2103481
N Engl J Med 2021; 384:e91
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
doi : 10.1056/NEJMx210006
N Engl J Med 2021; 384:e92
